Claims for Patent: 10,029,015

Summary for Patent: 10,029,015

Title:	Hydrogel formulations
Abstract:	A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.
Inventor(s):	Hersel; Ulrich (Heidelberg/Hanschuhsheim, DE), Rau; Harald (Heidelberg, DE), Schnepf; Robert (Heidelberg/Dossenheim, DE), Vetter; Dirk (Heidelberg/Neuenheim, DE), Wegge; Thomas (Heidelberg/Ziegelhausen, DE)
Assignee:	ASCENDIS PHARMA A/S (Hellrup, DK)
Application Number:	14/707,464
Patent Claims:	1. A polymeric prodrug hydrogel composition, comprising a hydrogel having mesopores of pore size between 1 and 100 nm with surface openings, the mesopores containing therein prodrug linker covalently bonded to the mesopore, the prodrug linker being reversibly covalently bonded by a reversible covalent bond to a biologically active moiety so that the biologically active moiety is contained in the mesopore, the mesopores having average pore size larger than the diameter of the biologically active moiety, the biologically active moiety being coupled only to mesopores in the hydrogel, the reversible covalent bond of the prodrug linker being cleavable in vivo to release the biologically active moiety from the composition so that the biologically active moiety can freely diffuse out of the mesopores of the hydrogel, wherein the hydrogel is degradable in vivo, and wherein the polymeric prodrug hydrogel composition is constituted with respect to its hydrogel, prodrug linker and reversible covalent bond to the biologically active moiety so that release properties of the active biological moiety from the composition are governed by the prodrug linker cleavage kinetics, with said prodrug linker being constituted to provide a cleavage rate in vivo that is at least an order of magnitude higher than rate of degradation of said hydrogel in vivo. 2. The polymeric prodrug hydrogel composition according to claim 1, wherein the biologically active moiety is a biopolymer. 3. The polymeric prodrug hydrogel composition according to claim 1, wherein the biologically active moiety is selected from the group of proteins or polypeptides consisting of ACTH, adenosine deaminase, agalsidase, albumin, alpha-1 antitrypsin (AAT), alpha-1 proteinase inhibitor (API), alteplase, anistreplase, ancrod serine protease, antibodies (monoclonal or polyclonal, and fragments or fusions), antithrombin III, antitrypsins, aprotinin, asparaginases, biphalin, bone-morphogenic proteins, calcitonin (salmon), collagenase, DNase, endorphins, enfuvirtide, enkephalins, erythropoietins, factor VIIa, factor VIII, factor VIIIa, factor IX, fibrinolysin, fusion proteins, follicle-stimulating hormones, granulocyte colony stimulating factor (G-CSF), galactosidase, glucagon, glucocerebrosidase, granulocyte macrophage colony stimulating factor (GM-CSF), phospholipase-activating protein (PLAP), gonadotropin chorionic (bCG), hemoglobins, hepatitis B vaccines, hirudin, hyaluronidases, idurnonidase, immune globulins, influenza vaccines, interleukins (1 alpha, 1 beta, 2, 3, 4, 6, 10, 11, 12), IL-1 receptor antagonist (rhIL-1ra), insulins, interferons (alpha 2a, alpha 2b, alpha 2c, beta 1a, beta 1b, gamma 1a, gamma 1b), keratinocyte growth factor (KGF), transforming growth factors, lactase, leuprolide, levothyroxine, luteinizing hormone, lyme vaccine, natriuretic peptide, pancrelipase, papain, parathyroid hormone, PDGF, pepsin, platelet activating factor acetylhydrolase (PAF-AH), prolactin, protein C, octreotide, secretin, sermorelin, superoxide dismutase (SOD), somatropins (growth hormone), somatostatin, streptokinase, sucrase, tetanus toxin fragment, tilactase, thrombins, thymosin, thyroid stimulating hormone, thyrotropin, tumor necrosis factor (TNF), TNF receptor-IgG Fc, tissue plasminogen activator (tPA), TSH, urate oxidase, urokinase, vaccines, and plant proteins. 4. The polymeric prodrug hydrogel composition of claim 1, wherein the biologically active moiety is insulin. 5. The polymeric prodrug hydrogel composition according to claim 1, wherein the biologically active moiety is an organic small molecule bioactive agent. 6. The polymeric prodrug hydrogel composition according to claim 5, wherein the biologically active moiety is selected from the group of organic small molecule bioactive agents consisting of central nervous system-active agents, anti-infective, anti-neoplastic, antibacterial, anti-fungal, analgesic, contraceptive, anti-inflammatory, steroidal, vasodilating, vasoconstricting, and cardiovascular agents. 7. The polymeric prodrug hydrogel composition of claim 1, wherein the biologically active moiety is an antisense or interfering oligonucleotide. 8. The polymeric prodrug hydrogel composition of claim 1, wherein the reversible prodrug linker comprises a masking group and an activating group. 9. The polymeric prodrug hydrogel composition of claim 1, wherein the reversible prodrug linker comprises a carbamate bond. 10. The polymeric prodrug hydrogel composition of claim 1, wherein the reversible prodrug linker has a functional group. 11. The polymeric prodrug hydrogel composition of claim 10, wherein the functional group is selected from the group of functional groups consisting of carboxylic acid and derivatives, carbonate and derivatives, hydroxyl, hydrazine, hydroxylamine, maleamic acid and derivatives, ketone, amino, aldehyde, thiol and disulfide groups. 12. The polymeric prodrug hydrogel composition of claim 1, wherein the hydrogel is synthesized from the group of polymers consisting of polyalkyloxy-based polymers, dextran, chitosan, hyaluronic acid and derivatives, alginate, xylan, mannan, carrageenan, agarose, cellulose, starch, hydroxyethyl starch (HES) and other carbohydrate-based polymers, poly(vinyl alcohols), poly(oxazolines), poly(anhydrides), poly(ortho esters), poly(carbonates), poly(urethanes), poly(acrylic acids), poly(acrylamides), poly(acrylates), poly(methacrylates), poly(organophosphazenes), poly(siloxanes), poly(vinylpyrrolidone), poly(cyanoacrylates), poly(esters), poly(iminocarbonates), and poly(amino acids). 13. The polymeric prodrug hydrogel composition of claim 12, wherein the polyalkyloxy-based polymer is poly(propylene glycol) or poly(ethylene glycol). 14. The polymeric prodrug hydrogel composition of claim 12, wherein the poly(acrylamide) is poly(hydroxypropylmethacrylamide) (HMPA). 15. The polymeric prodrug hydrogel composition of claim 12, wherein the poly(methacrylate) is poly(hydroxyethylmethacrylate). 16. The polymeric prodrug hydrogel composition of claim 12, wherein the poly(ester) is poly(lactic acid) or a poly(glycolic acid). 17. The polymeric prodrug hydrogel composition of claim 12, wherein the poly(amino acid) is poly(glutamic acid), collagen, or gelatin. 18. The polymeric prodrug hydrogel composition of claim 1, wherein the hydrogel is polyacrylamide or a derivative thereof. 19. The polymeric prodrug hydrogel composition of claim 1, wherein the hydrogel is poly(ethylene glycol acrylamide) or a derivative thereof. 20. The polymeric prodrug hydrogel composition of claim 1, wherein cross-linkers of the hydrogel further comprise biodegradable bonds selected from the group of chemically cleavable bonds consisting of phosphate, phosphonate, carbonate, carbamate, disulfide and ester bonds. 21. The polymeric prodrug hydrogel composition of claim 1, further comprising biodegradable bonds selected from the group of chemically cleavable bonds consisting of phosphate, phosphonate, carbonate, carbamate, disulfide and ester bonds. 22. The polymeric prodrug hydrogel composition of claim 1, further comprising biodegradable bonds which are enzymatically cleavable.

Details for Patent 10,029,015

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2024-07-05
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2024-07-05
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2024-07-05
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2024-07-05
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	03/26/1974		2024-07-05